High frequency of osteonecrosis of the jaw among denosumab-treated prostate cancer patients.

The article discusses the disease of osteonecrosis in jaw treated with the class of drugs incluidng denosumaba and bisphosphonates in the patients of prostate cancer. The report is based on the case series of patients with castration-resistant prostate cancer (CRPC) along with the complications of bone metastases. The patients are treated with the infusion of zoledronic acid, use of denosumab antibody helpful in the prevention of the skeletal-related events (SREs).